Summit Lens

Eva
  • 5.0 (2)
  • Life Sciences
  • Biweekly

Healthcare is shaped by three forces: patients, policy, and products. Summit Lens explores what happens when science meets the real world — when a discovery becomes a drug, a drug meets the healthcare system, and new technologies change how medicine is developed and delivered. Each episode starts with one question and follows it through the system, so you come away understanding how healthcare works, why it matters, and what to watch next. Hosted by Shanyue.

  1. Oct 26

    When Government Gets an AI Copilot

    AI is helping pharmaceutical companies develop drugs. Now, the FDA has an AI assistant to help review the evidence. But that's just the beginning. Across American healthcare, government agencies are increasingly using AI to review medical payments, document patient visits, and support biomedical research. So what happens when the institutions responsible for regulating, paying for, and delivering healthcare start using AI themselves? In this episode, we explore FDA's Elsa, Medicare's WISeR model, AI-assisted clinical documentation at the VA, and research initiatives from NIH and ARPA-H. Along the way, we examine the promises of greater efficiency and the harder questions about accuracy, financial incentives, human oversight, and accountability. Because making a process faster doesn't necessarily mean making it better. The question is: faster for whom, and what happens to the person waiting? Timestamps 00:00 When Government Gets an AI Copilot02:09 FDA: AI at the Reviewer's Desk05:44 CMS: When a Patient Is Waiting09:43 Medicare WISeR: The Hidden Work Behind AI Efficiency14:19 VA: AI in the Exam Room17:04 NIH & ARPA-H: Building the Future of AI Research19:47 Who Is Accountable When AI Gets It Wrong?22:15 Back to the FDA Table

  2. Sep 27

    Can AI Build a Drug?

    AI can predict protein structures, search enormous chemical spaces, identify drug targets, and help design new molecules. But building a molecule is only the beginning. In this episode, we follow one fictional cancer drug, SL-101, through the modern R&D pipeline—from target discovery and medicinal chemistry to Phase II, biomarker selection, clinical trials, and one of the hardest decisions in pharma: whether to keep spending. Along the way, we look at how companies such as Insilico Medicine, Recursion, Isomorphic Labs, Tempus, Schrödinger, and Unlearn are applying very different kinds of AI to very different problems. The deeper question is whether AI can help pharma make better bets: choosing the right target, the right molecule, the right patient, and knowing when a program is no longer worth funding. Timestamps 00:00 A Drug at a Crossroads04:17 What Should We Drug? AI Target Discovery13:16 What Molecule Should We Make?20:50 When Biology Fights Back: Phase I vs. Phase II30:00 Who Actually Responds? Biomarkers and Patient Selection37:25 When Should We Stop Spending? The Value of Failing Early42:04 Can AI Make Clinical Trials Better?48:43 Who Owns the Value? Big Pharma vs. AI Biotech53:02 A Sequence of Better Bets

  3. Sep 13

    When AI Enters the Exam Room

    AI can already read scans, flag high-risk patients, guide ultrasound exams, and even make some autonomous diagnostic decisions. But that raises a more important question: does a better model actually lead to better care? In this episode, we follow what happens after the algorithm gives an answer. We look at why GPT-4 did not automatically make physicians better diagnosticians, how AI cut mammography reading workload by 44%, why some clinical alerts become noise while others speed up stroke treatment, and what happens when AI moves expertise closer to the patient. We also look at one of the rare randomized trials linking an AI alert to lower mortality—and why some of the fastest-moving healthcare AI may be doing something far less glamorous: writing the clinical note. The real story of medical AI may not be whether machines can outperform doctors. It may be whether healthcare systems know what to do with what the machines find. Timestamps 00:08 The rise of AI in medicine05:33 When smart AI doesn’t automatically make a smarter team09:14 When the workflow is designed around AI13:31 When an alert becomes noise19:25 When the signal reaches an outcome22:33 Moving expertise closer to the patient28:21 Why the “boring” AI may move faster31:24 Who decides when AI is good enough for healthcare?

  4. Sep 7

    When Healthcare Becomes an Investment Thesis

    You may know your doctor. But do you know who owns the business around your doctor? Private equity usually does not show up in healthcare with a Wall Street label. It shows up more quietly, in the local practice that keeps its old name, the specialist group inside a hospital, or the clinic that suddenly feels more optimized than before. The care may look familiar. The ownership may not be. In this episode, we follow how private equity became one of the most important and least visible ownership forces in the US healthcare. The story starts with the private equity model itself: raise capital, use leverage, buy a platform, add smaller practices, centralize operations, optimize revenue, and sell on a fund timeline. Then we ask why healthcare fit that model so well. The answer is uncomfortable: fragmented providers, opaque prices, third-party payment, complex billing, recurring demand, and physicians exhausted by the business side of medicine. We follow that playbook from physician practices to emergency staffing, outpatient specialties, nursing homes, and hospital real estate. This is not a simple story about private equity being good or bad. Some practices need capital. Some physicians sell for rational reasons. Some platforms bring better technology and cleaner operations. But when care becomes an investment asset, the logic around the exam room can change: what gets scheduled, what gets billed, which services grow, how doctors practice, and what patients experience without ever seeing the ownership change. The takeaway is simple: In the US healthcare, ownership is now part of the care model. The question is no longer only, “Who is my doctor?” It is also, “Who owns the system around my doctor and what is that owner optimized to do?” Timestamps 00:07 When Healthcare Becomes an Investment Thesis04:03 How the Private Equity Model Works08:46 Why Healthcare Fit the Financial Engine10:29 The Roll-Up Playbook16:38 Envision, Surprise Billing, and the No Surprises Act26:43 Specialty Roll-Ups and Outpatient Care32:36 When Financial Engineering Hits High-Risk Care39:31 What Changes for Doctors, Patients, and Prices43:19 How Regulators Are Pushing Back47:15 Who Owns the System Around Your Doctor?

  5. Aug 30

    Why Hospitals Became the Price Setters

    Why can the same care cost more when the doctor, the room, and the service have not changed? In this episode, we look at how hospitals became some of the most powerful price setters in American healthcare. We start with a routine cardiology visit that suddenly costs almost three times more after the practice becomes part of a hospital system. From there, we unpack the larger structure behind that bill: hospital consolidation, must-have health systems, commercial prices, facility fees, physician practice acquisitions, and the policy fight over site-neutral payments. This is not a simple story about hospitals being good or bad. Some health systems have enormous leverage. Some rural hospitals are barely staying open. And many policy solutions come with real tradeoffs. But the central tension is clear: in healthcare, scale can create survival — and scale can create pricing power. Timestamps 00:06 Why Hospitals Became the Price Setters05:34 Hospitals as the Load-Bearing Wall of Healthcare Spending12:10 Three Consolidation Playbooks15:42 When the Bargaining Table Tips19:07 Commercial Prices and the Cross-Subsidy Debate25:21 Facility Fees and the Site-of-Care Economy30:14 The Site-Neutrality Fight33:06 Physician Practice Acquisition and Referral Control34:27 The Anticompetitive Mechanisms Behind Doctor Buyouts37:01 The Invisibility Problem in Healthcare Acquisitions40:50 The Rural Hospital Tradeoff45:15 Four Ways the System Pushes Back52:37 Why Hospital Market Power Matters

  6. Aug 19

    Why Having Insurance Still Feels Expensive

    What does it actually mean to have health insurance in America? In this episode, we look at the Affordable Care Act not as a partisan debate, but as a systems story. The ACA changed who could enter the insurance market. It made it harder for insurers to deny coverage because of pre-existing conditions, removed annual and lifetime limits, expanded Medicaid in many states, and created subsidized marketplaces for people outside employer coverage. But it did not fully change what care costs once someone gets inside the system. So the central question is not simply whether the ACA succeeded or failed. It is what kind of problem the law was built to solve, and what kind of problem it left behind. We follow that question from a kitchen table during open enrollment to pre-ACA medical underwriting, marketplace plan design, narrow networks, underinsurance, Medicaid expansion, temporary subsidies, and the deeper cost structure underneath American healthcare. Because having insurance is not always the same as being able to afford care. Timestamps 00:05 Why Having Insurance Still Feels Expensive05:47 Before the ACA: The Exclusion Problem13:36 How the ACA Rebuilt Insurance22:41 When Coverage Is Hard to Use33:16 Why Premiums and Deductibles Keep Rising38:42 The Medicaid Expansion Divide44:15 Temporary Subsidies and the 2026 Shock48:39 What the ACA Solved and What It Didn’t54:40 The Core Tradeoff and What Comes Next

  7. Aug 11

    When Washington Becomes the Drug Price Negotiator

    What happens when Medicare stops only paying for drugs and starts naming the price? In this episode, we look at the Inflation Reduction Act and Medicare drug price negotiation, not as a policy explainer, but as a shift in power inside the U.S. drug market. For nearly two decades, Medicare Part D relied on private plans, PBMs, formularies, and rebates to negotiate drug costs. The IRA changed that architecture. Washington is now setting prices for selected high-spend Medicare drugs, and every part of the system is adapting around that new signal. We follow the story from the pharmacy counter to the manufacturer revenue model, the Part D plan bid, the PBM rebate negotiation, and the biotech investment decision. The question is no longer only whether Medicare can negotiate a lower price. It is what happens when that price becomes part of the operating system for the US drug markets. Timestamps 00:10 Drug Pricing and the IRA05:15 Medicare’s Old Bargain10:05 How Washington Names a Price13:46 Which Drugs Got Picked and Why27:54 The Hidden Half: Part D Redesign37:33 Pharma’s Strategic Response46:32 PBMs Adapt, Not Disappear51:00 What Patients Actually Experience56:55 The New Price Signal

  8. Jun 15

    When GLP-1 Meets the Real World

    GLP-1 proved the science could work. The harder test began once patients tried to get it. In this episode, we follow GLP-1 from the pharmacy counter into the real world of American healthcare: insurance coverage, compounding pharmacies, PBM formulary decisions, employer benefit design, cash pay pathways, TrumpRx, and public policy. The question is no longer only whether these drugs work. It is how the system decides who gets access when a treatment is effective, expensive, highly demanded, and potentially preventive. And for many patients, the answer depends on which door is actually open. Timestamps 00:06  When the Prescription Isn’t Enough07:47  How Compounding Became the Workaround10:58  Why Coverage Still Creates Friction16:17  Public Coverage and International Contrasts21:53  PBMs, Employers, and the Formulary Fight28:56  Cash Pay, TrumpRx, and New Access Lanes35:19  The Pipeline Keeps Moving35:48  Who Pays for Prevention?

See All (14)

Ratings & Reviews

5
out of 5
2 Ratings

About

Healthcare is shaped by three forces: patients, policy, and products. Summit Lens explores what happens when science meets the real world — when a discovery becomes a drug, a drug meets the healthcare system, and new technologies change how medicine is developed and delivered. Each episode starts with one question and follows it through the system, so you come away understanding how healthcare works, why it matters, and what to watch next. Hosted by Shanyue.

Information

  • Creator
    Eva
  • Years Active
    2026
  • Episodes
    14
  • Rating
    Clean
  • Copyright
    © Eva
  • Show Website
    Summit Lens